| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.083 | 0.2 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.2 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |